News & Updates
Filter by Specialty:
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
Treatment with osimertinib following chemoradiotherapy (CRT) helps lower the risk of distant metastases and central nervous system (CNS) disease progression in patients with unresectable stage III epidermal growth factor receptor-mutated (EGFRm) nonsmall cell lung cancer (NSCLC), results of the phase III LAURA study have shown.
Osimertinib reduces risk of metastasis, CNS progression in NSCLC
13 Dec 2024
Ribociclib plus radiotherapy feasible in metastatic breast cancer
The addition of CDK4/6 inhibitor ribociclib to palliative radiotherapy is relatively safe in patients with metastatic breast cancer, reports a study.
Ribociclib plus radiotherapy feasible in metastatic breast cancer
13 Dec 2024
CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC
The phase III CROWN trial previously showed that first-line treatment with lorlatinib, a third-generation ALK tyrosine kinase inhibitor (TKI), provided significant survival benefits vs crizotinib in patients with treatment-naïve, advanced, ALK-positive non-small-cell lung cancer (NSCLC). At the 2024 World Conference on Lung Cancer, CROWN investigators discussed the patterns of progression and management of adverse events (AEs) associated with lorlatinib after 5 years of follow-up.
CROWN study at 5 years: Sustained benefits with lorlatinib in advanced ALK-positive NSCLC
13 Dec 2024
Metformin improves responses to chemotherapy in nondiabetic breast cancer
Use of metformin in nondiabetic breast cancer patients improves their clinical and pathological response to neoadjuvant AC-T chemotherapy, reveals a recent study.
